NeuroSense Therapeutics (NRSN) Fundamentals 2026 — Revenue Analysis | SniperIQ
NeuroSense Therapeutics (NRSN) is a IL-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is NeuroSense Therapeutics's market cap?
NeuroSense Therapeutics (NRSN) has a market capitalization of approximately
How profitable is NeuroSense Therapeutics?
NeuroSense Therapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does NeuroSense Therapeutics pay a dividend?
NeuroSense Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is NeuroSense Therapeutics financially healthy?
NeuroSense Therapeutics carries a debt-to-equity ratio of -0.11x and a current ratio of 0.31x, with a market beta of 1.56. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is NeuroSense Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For NeuroSense Therapeutics (NRSN) the key facts are: market cap
Track NeuroSense Therapeutics's full fundamentals live
Get NeuroSense Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.